Difopein
目录号 : GC16682
14.3.3 protein inhibitor
Cas No.:396834-58-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: ≥90.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Difopein is an inhibitor of 14-3-3 protein.
14-3-3 protein has been involved in a wide range of biologic processes such as signal transduction, vesicular transport, cell cycle control, DNA replication, DNA repair and apoptosis. 14-3-3 protein has been associated with tumor genesis. 14-3-3 protein correlates with reduced tumor cell apoptosis and abbreviated patient survival. Up-regulation of 14-3-3 protein provides a survival advantage to tumor cells. Inhibition of 14-3-3 protein might trigger apoptosis, inhibit growth of established tumors, suppress de novo tumor formation, and promise a novel therapeutic approach for glioma treatment [1].
In human glioma U251 and U87 cells, difopein resulted in apoptosis characteristics, such as nuclear fragmentation, DNA laddering fragment and appearance of membrane-enclosed apoptotic bodies. Difopein induced apoptosis in a time-dependent manner [1]. Difopein induced glioma cell apoptosis through down-regulating Bcl-2, up-regulating Bax and activating caspase-9 and caspase-3. In vivo, difopein effectively hindered proliferation and triggered apoptosis of tumor cells implanted into nude mice [1].
Reference:
[1] Cao W, Yang X, Zhou J, et al. Targeting 14-3-3 protein, difopein induces apoptosis of human glioma cells and suppresses tumor growth in mice[J]. Apoptosis, 2010, 15(2): 230-241.
| Cas No. | 396834-58-5 | SDF | |
| 分子式 | C273H424N76O89S6 | 分子量 | 6387.17 |
| 溶解度 | Soluble to 5 mg/ml in Water | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.1566 mL | 0.7828 mL | 1.5656 mL |
| 5 mM | 0.0313 mL | 0.1566 mL | 0.3131 mL |
| 10 mM | 0.0157 mL | 0.0783 mL | 0.1566 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。